Clover Health Investments shares are trading lower. UBS initiated coverage on the stock with a Neutral rating and announced a price target of $4.
Portfolio Pulse from Benzinga Newsdesk
Clover Health Investments shares are trading lower following UBS's initiation of coverage with a Neutral rating and a price target of $4.
October 07, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS initiated coverage on Clover Health Investments with a Neutral rating and a $4 price target, leading to a decline in the stock price.
The Neutral rating and $4 price target from UBS likely contributed to the decline in Clover Health's stock price, as investors may have adjusted their expectations based on this new analyst coverage.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100